Sana Biotechnology will present preclinical data for SG293, an in vivo CAR T candidate, at ASGCT 2026. The presentation covers a CD8-targeted fusosome that generates CD19-directed CAR T cells in NHPs.
Vertex secured a Germany reimbursement agreement for CASGEVY and signed a WuXi Biologics pact for a preclinical autoimmune T-cell engager. The moves add to efforts to build revenue beyond cystic fibrosis.
The iPSC-derived NK cells pipeline includes 12+ active players and 15+ drugs in development. FT522 is in Phase I, while CNTY-101 and NCR300 are among other programs in the clinic.
